CAS 356-12-7|FLUOCINONIDE

Introduction:Basic information about CAS 356-12-7|FLUOCINONIDE, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Common NameFLUOCINONIDE
CAS Number356-12-7Molecular Weight494.525
Density1.3±0.1 g/cm3Boiling Point591.1±50.0 °C at 760 mmHg
Molecular FormulaC26H32F2O7Melting Point309ºC
MSDSChineseUSAFlash Point311.3±30.1 °C
Symbol
GHS06, GHS08
Signal WordDanger

Names

NameFluocinolone Acetonide Acetate
SynonymMore Synonyms

FLUOCINONIDE BiologicalActivity

DescriptionFluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders.Target: Glucocorticoid ReceptorFluocinonide is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. Fluocinonide ranks as a "high-potency" topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects. Fluocinonide should not be used if infection is present. Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs. Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure. From Wikipedia.
Related CatalogSignaling Pathways >>GPCR/G Protein >>Glucocorticoid ReceptorResearch Areas >>Inflammation/Immunology
References

[1]. http://en.wikipedia.org/wiki/Fluocinonide

Chemical & Physical Properties

Density1.3±0.1 g/cm3
Boiling Point591.1±50.0 °C at 760 mmHg
Melting Point309ºC
Molecular FormulaC26H32F2O7
Molecular Weight494.525
Flash Point311.3±30.1 °C
Exact Mass494.211609
PSA99.13000
LogP3.36
Vapour Pressure0.0±3.8 mmHg at 25°C
Index of Refraction1.560
InChIKeyWJOHZNCJWYWUJD-IUGZLZTKSA-N
SMILESCC(=O)OCC(=O)C12OC(C)(C)OC1CC1C3CC(F)C4=CC(=O)C=CC4(C)C3(F)C(O)CC12C

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TU3831000
CHEMICAL NAME :
Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic 17-acetal with acetone, 21-acetate
CAS REGISTRY NUMBER :
356-12-7
LAST UPDATED :
199709
DATA ITEMS CITED :
11
MOLECULAR FORMULA :
C26-H32-F2-O7
MOLECULAR WEIGHT :
494.58
WISWESSER LINE NOTATION :
T F5 E5 B666 GO IO RV AHTTTT&J A1 BF CQ E1 FV1OV1 H1 H1 OF

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
14 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
300 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
720 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>6 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
160 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
165 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
>3170 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Administration onto the skin
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
3750 ug/kg/30D-I
TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
3 mg/kg
SEX/DURATION :
female 3 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
4 gm/kg
REFERENCE :
BJDEAZ British Journal of Dermatology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.63- 1951- Volume(issue)/page/year: 94,1,1976 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X6123 No. of Facilities: 52 (estimated) No. of Industries: 2 No. of Occupations: 4 No. of Employees: 10431 (estimated) No. of Female Employees: 9606 (estimated)

Safety Information

Symbol
GHS06, GHS08
Signal WordDanger
Hazard StatementsH300-H361
Precautionary StatementsMissing Phrase - N15.00950417-P280
Hazard CodesT+: Very toxic;
Risk PhrasesR28
Safety Phrases22-25-28-36/37/39-45
RIDADRUN 2811 6.1/PG 2
WGK Germany3
RTECSTU3831000
Packaging GroupI
Hazard Class6.1(a)
HS Code2937210000

Customs

HS Code2937210000

Articles27

More Articles
Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.

Journal. of. Drugs in. Dermatology. 10(2) , 171-6, (2011)

To determine the effect a novel formulation of fluocinonide cream on skin barrier function in subjects with atopic dermatitis.The authors performed an open-label, investigator-blinded, side-by-side, c...

Urticarial hypersensitivity reaction caused by temozolomide.

Journal. of. Drugs in. Dermatology. 9(9) , 1142-4, (2010)

Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from...

In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.

Journal. of. Drugs in. Dermatology. 7(1) , 28-32, (2008)

Prolonged topical corticosteroid use is often associated with atrophic skin changes. This trial compared signs of skin atrophy related to 3 super-high-potency corticosteroids: fluocinonide 0.1% cream,...

Synonyms

2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluor-5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-6b-yl]-2-oxo
Ethylacetat
acétate de 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a,8,8-tétraméthyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodécahydro-6bH-naphto[2',1':4,5]indéno[1,2-d][1,3]dioxol-6
16a,17a-Isopropylidene-6a-fluorotriamcinolone 21-Acetate
6a,9-Difluoro-11b,16a,17,21-tetrahydroxypregna-1,4-diene-3,20-dione Cyclic 16,17-Acetal with Acetone 21-Acetate
FLUOCINONIDE
2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-6b-yl]-2-ox
2H-naphth[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one, 6b-[(acetyloxy)acetyl]-4b,12-difluoro-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-5-hydroxy-4a,6a,8,8-tetramethyl-, (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-
2H-Naphth[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one, 6b-[2-(acetyloxy)acetyl]-4b,12-difluoro-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-5-hydroxy-4a,6a,8,8-tetramethyl-, (4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-
2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluor-5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-6b-yl]-2-oxoethylacetat
21-Acetoxy-6a,9a-difluoro-11b-hydroxy-16a,17a-isopropylidenedioxy-1,4-pregnadiene-3,20-dione
oethyl acetate
21-(Acetyloxy)-6a,9-difluoro-11b-hydroxy-16a,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione
Topsym
acétate de 2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-4a,6a,8,8-tétraméthyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodécahydro-6bH-naphto[2',1':4,5]indéno[1,2-d][1,3]dioxol-6b-yl]-2-oxoéthyle
2-[(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-Difluoro-5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-6b-yl]-2-oxoethyl acetate
CAS 84-19-5|Relaton-Oral
CAS 3057-04-3|Chenodiol methyl ester
Recommended......
TOP